Greg Rodgers

On June 6, 2024, UGI Corporation (NYSE: UGI) announced the pricing of its offering of US$610,000,000 aggregate principal amount of 5.00% convertible senior notes due 2028 in a private offering. Latham & Watkins LLP represents UGI in the offering with a corporate team led by Houston partners Ryan Maierson and Kevin Richardson, Los Angeles/New York partner Greg Rodgers, and Los Angeles partner Arash Aminian Baghai, with associates Sydney Verner, Brian Bruzzo, Armaan Bhimani, David Lee, Ryan Gold, and Andrew Bentz. Advice was also provided on tax matters by New York partner Elena Romanova, Houston partners Tim Fenn and Bryant Lee, with associate Farrah Yan; on environmental matters by Los Angeles/Houston partner Josh Marnitz; and on finance matters by Houston partner Catherine Ozdogan and Houston counsel Bryce Kaufman.~~

Jun 10

1 min

Pacira BioSciences, Inc. (Nasdaq: PCRX) has announced the pricing of US$250 million aggregate principal amount of convertible senior notes due 2029 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional US$37.5 million aggregate principal amount of notes. Pacira intends to use the proceeds from the offering to repurchase existing outstanding convertible notes and shares of its common stock, and for general corporate purposes, including working capital, and research and development expenditures. Latham & Watkins LLP advised the initial purchasers of notes with a capital markets team led by Los Angeles/New York partner Greg Rodgers and New York Partner Nathan Ajiashvili, with associates Ryan Gold, Roger Yarett, Andrew Bentz, and Richard Dacher. Advice was provided on derivatives matters by New York partner Eric Rice, with associates Shawn Noh and Henry Lin; and on tax matters by New York partner Elena Romanova, with associate James Aldred.~~

May 10

1 min

OSI Systems, Inc. (NASDAQ: OSIS), a vertically integrated designer and manufacturer of specialized electronic systems and components, has announced the pricing of its offering of US$300 million aggregate principal amount of 2.25% convertible senior notes due 2029 in a private offering. The offering size was increased from the previously announced offering size of US$275 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on July 19, 2024, subject to customary closing conditions. OSI also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional US$50 million principal amount of notes. Latham & Watkins LLP represents OSI Systems in the offering with a capital markets team led by New York/Los Angeles partners Greg Rodgers and Brittany Ruiz and Orange County partner Michael Treska, with associates Ryan Gold, Paul Lau, William Coughlin, Dylan Shamoon, and Daniel Weiss. Advice on tax matters was provided by New York partners Bora Bozkurt and Aaron Bernstein, with associate Farrah Yan.~~

Jul 18

1 min

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), has announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining US$75 million of its Pharmakon Advisors term loan. Under the terms of the royalty monetization facility, Coherus received US$37.5 million in return for a certain net sales royalty percentage consideration on US sales of LOQTORZI® and UDENYCA® up to a hard cap. Under the term loan, Coherus received US$38.7 million in proceeds from a structured debt loan with a May 2029 maturity. Latham & Watkins LLP represented Coherus in the transaction with a corporate deal team led by Bay Area partners Jekkie Kim, Dan Van Fleet, Ben Potter, and Phillip Stoup, with associates Mizuna Sekine, Trevor Church, Patrick Chew, and Rychelle Andersen. Advice was also provided on tax matters by partners Eric Cho and Katharine Moir, with associates Sam Yang and Rasha Suleiman; on security matters by counsel Emily Yu; on healthcare regulatory matters by Washington, D.C. counsel Chad Jennings; and on convertible debt related matters by Los Angeles/New York partner Greg Rodgers.~~

May 13

1 min

Health Catalyst, Inc. (Nasdaq: HCAT) (Health Catalyst), a leading provider of data and analytics technology and services to healthcare organizations, has announced that it has entered into a new credit facility provided by Silver Point Finance, the direct lending business of Silver Point Capital, L.P. The new credit facility provides up to US$225 million in committed capital which consists of (i) an initial term loan facility in an aggregate principal amount of US$125 million and (ii) a delayed draw term loan facility in an aggregate principal amount of US$100 million. Latham & Watkins LLP advised Health Catalyst in the transaction with a deal team led by transactional partners Jennifer Kent and Haim Zaltzman, with associates Hyunji Lee, Samantha Kosarzycki, and Lindsay Kenney. Advice was also provided on certain corporate matters by partners Rick Kline, Erica Kassman, Christopher Clark, Reza Mojtabaee-Zamani, and Greg Rodgers, with associates Shawn Noh, Julian Brody, and Kayleigh Kuyon; on tax matters by partner Grace Lee, with associate Dennis Poehland; on intellectual property matters by partner Michelle Gross, with associate Andrew Abokhair; on healthcare regulatory matters by partner Betty Pang, with counsel Chad Jennings; on data privacy matters by partner Heather Deixler, with associate Mitch Bennett; on ERISA matters by counsel Aryeh Zuber; on real estate matters by partner Dara Denberg; on UK matters by associate Corrie Eames; and on certain other regulatory matters by partner Joseph Bargnesi, counsel Joel Cavanaugh, with associate Eric Green.~~

Jul 19

1 min